PURE Bioscience (OTCMKTS:PURE) Sees Significant Drop in Short Interest

PURE Bioscience (OTCMKTS:PURE) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 2,900 shares, a decline of 29.3% from the September 30th total of 4,100 shares. Based on an average daily trading volume, of 45,400 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are short sold. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 45,400 shares, the short-interest ratio is presently 0.1 days.

PURE Bioscience Stock Performance

Shares of PURE stock opened at $0.06 on Wednesday. PURE Bioscience has a fifty-two week low of $0.05 and a fifty-two week high of $0.21. The stock’s fifty day moving average is $0.08 and its two-hundred day moving average is $0.08. The firm has a market capitalization of $6.72 million, a P/E ratio of -1.50 and a beta of 0.41.

PURE Bioscience (OTCMKTS:PURE) last issued its earnings results on Wednesday, October 29th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $1.71 million for the quarter.

About PURE Bioscience

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.